Because BCR is an imprecise predictor of progression and PC death, it is also logical to see if men can be risk-stratified for treatment (none or delayed) using DT to avoid treatment-related complications, reduction in quality of life, and expense. This evidence concerns the gene BCR and pachyonychia congenita.